Literature DB >> 12872031

Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular disease?

Massimo Volpe1, Beatrice Musumeci, Paola De Paolis, Carmine Savoia, Alberto Morganti.   

Abstract

The renin-angiotensin system (RAS) plays a pivotal role in the regulation of fluid, electrolyte balance and blood pressure, and is a modulator of cellular growth and proliferation. Biological actions of RAS are linked to the binding of the effector molecule, angiotensin II (AngII), to specific membrane receptors, mostly the AT1 subtype and, to a lesser extent, other subtypes. Following the identification and characterization of the AT2 subtype receptor, it has been proposed that a complex interaction between AngII and its receptors may play an important role in the effects of RAS. In this paper current information on AngII subtype receptors--their structure, regulation and intracellular signalling--are reviewed, with a particular emphasis on the potential relevance for cardiovascular pathophysiology. In addition, we discuss modulation of expression of the AT2 receptor and its interaction with the AT1 receptor subtype, as well as the potential effects of this receptor on blood pressure regulation. A better understanding of the integrated effects of the AngII subtype receptors may help to elucidate the function of the RAS, as well as their participation in the mechanisms of cardiovascular disease and attendant therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12872031     DOI: 10.1097/00004872-200308000-00001

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  17 in total

Review 1.  Direct renin inhibition: from pharmacological innovation to novel therapeutic opportunities.

Authors:  Massimo Volpe; Roberto Pontremoli; Claudio Borghi
Journal:  High Blood Press Cardiovasc Prev       Date:  2011-09-01

2.  RAAS polymorphisms alter the acute blood pressure response to aerobic exercise among men with hypertension.

Authors:  Bruce E Blanchard; Gregory J Tsongalis; Margaux A Guidry; Lisa A LaBelle; Michelle Poulin; Amy L Taylor; Carl M Maresh; Joseph Devaney; Paul D Thompson; Linda S Pescatello
Journal:  Eur J Appl Physiol       Date:  2006-02-09       Impact factor: 3.078

Review 3.  Angiotensin II-receptor antagonist in the treatment of hypertension.

Authors:  Massimo Volpe; Giuliano Tocci; Erika Pagannone
Journal:  Curr Hypertens Rep       Date:  2005-08       Impact factor: 5.369

Review 4.  End-organ protection in patients with hypertension: focus on the role of angiotensin receptor blockers on renal function.

Authors:  Giuliano Tocci; Massimo Volpe
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

5.  Developmental changes in AT1 and AT2 receptor-protein expression in rats.

Authors:  Li Yu; Mingqi Zheng; Wei Wang; George J Rozanski; Irving H Zucker; Lie Gao
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2010-08-31       Impact factor: 1.636

6.  Candesartan improves survival following severe hypovolemia in pigs; a role for the angiotensin II type 2 receptor?

Authors:  Mats Laesser; Emma Spak; Sara Ewert; Anders Aneman; Lars Fandriks
Journal:  Intensive Care Med       Date:  2005-06-28       Impact factor: 17.440

7.  High angiotensin II state without cardiac remodeling (Bartter's and Gitelman's syndromes): are angiotensin II type 2 receptors involved?

Authors:  L A Calò; R Montisci; R Scognamiglio; P A Davis; E Pagnin; S Schiavo; P Mormino; A Semplicini; P Palatini; A D'Angelo; A C Pessina
Journal:  J Endocrinol Invest       Date:  2009-07-14       Impact factor: 4.256

8.  Increased angiotensin II AT1 receptor mRNA and binding in spleen and lung of AT2 receptor gene disrupted mice.

Authors:  Jaroslav Pavel; José A Terrón; Julius Benicky; Alicia Falcón-Neri; Amita Rachakonda; Tadashi Inagami; Juan M Saavedra
Journal:  Regul Pept       Date:  2009-09-17

9.  Cardiovascular risk in hypertension - can we ask for more? : focus on aliskiren.

Authors:  Massimo Volpe
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-01-22

Review 10.  Candesartan in heart failure.

Authors:  Toni L Ripley; Jennifer S Chonlahan; Robin E Germany
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.